Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 1851–1900 of 18616
Mr. Wood’s employment with Adaptimmune Limited will end on August 31, 2025 (the “Revised Termination Date”) by reason of redundancy.
On the same date, to fill the vacancy, the Board elected Sam Zheng Sun as a Director of the Company and Chairperson of the Board of Directors, as well as appointed Sam Zheng Sun as the Chief Executive Officer of the Company.
Effective April 14, 2025, Bian Fan was removed as Director, Chairperson of the Board of Directors and Chief Executive Officer of DT Cloud Star Acquisition Corporation (the “Company”) by the written consent of the board
On April 11, 2025, Richard Tarapchak was promoted and appointed as the Chief Financial Officer of the Company and its subsidiaries and was designated as the Company’s Principal Financial Officer.
On April 14, 2025, Verano Holdings Corp., a British Columbia corporation (the “ Company ”), announced that Brett Summerer resigned as Chief Financial Officer of the Company and from all officer and other positions with its subsidiaries.
appointed Ben C. Rodgers to the role of executive vice president and chief financial officer, effective as of May 12, 2025
At the same time the Board appointed Shrilakshmi Vadlapatla as CFO.
On April 11 th , 2025, James Cardwell resigned his position as CFO of the Corporation.
the executive officers of the Company are: • Andrew Milgram, Chief Executive Officer; • Paul Arrouet, President; and • Jeffrey Kravetz, Chief Financial Officer.
the executive officers of the Company are: • Andrew Milgram, Chief Executive Officer; • Paul Arrouet, President; and • Jeffrey Kravetz, Chief Financial Officer.
the Board of Directors (the “Board”) of the Company appointed Mr. David Ayanoglou to serve as the Company’s Chief Financial Officer, effective immediately.
On April 8, 2025, Mr. Thyagarajan Ramachandran informed the Company that they had decided to resign from their position as the Chief Financial Officer of the Company, effective April 10, 2025, along with the appointment of Mr. David Ayanoglou as the new Chief Financial Officer of the Company.
On February 26, 2025, RBB Bancorp (the “Company”) and its wholly-owned subsidiary, Royal Business Bank (the “Bank”), entered into an Agreement and Release of Claims (the “Retirement Agreement”) with Mr. David Morris, the Company’s Chief Executive Officer, confirming the terms of his retirement and voluntary termination of his employment following the next annual meeting of the Company’s shareholders, which is expected to be held May 21, 2025.
On April 11, 2025, Timothy Foufas resigned as Co-Chief Executive Officer of The LGL Group, Inc. ("LGL Group" or the "Company"), effective May 1, 2025.
On April 11, 2025, the Board of Directors of vTv Therapeutics Inc. (the “Company”) appointed Barry K. Brown, age 64, as interim principal financial officer effective immediately.
The Board of the Company appointed Ti Chieh Zang (age 36) as the Director, Chief Executive Officer and Chief Financial Officer, effective on April 9, 2025.
Tak Chun Wong, the Director, Chief Executive Officer and Chief Financial Officer of AFB Limited. (the "Company"), is no longer holding the positions.
appointed Sheryl A. Lisowski, the Company's Executive Vice President – Chief Accounting Officer and Treasurer, to serve in the additional role of interim Chief Financial Officer of the Company, effective April 17, 2025
On April 9, 2025, James A.J. Nickolas notified Martin Marietta of his decision to resign as Executive Vice President and Chief Financial Officer, effective April 11, 2025
On April 10, 2025, the Company appointed Robert J. Cardin, age 61, to serve as the Company’s Interim Chief Financial Officer, effective as of the Transition Date
the Company announced the departure of Michael Shane Paladin, the Company’s President and Chief Executive Officer (“CEO”) and member of the Company’s Board of Directors (the “Board”) effective April 9, 2025.
The Company has appointed John Dorman, the Company’s Chairperson of the Board (“Board Chair”), as the Company’s interim President and interim Chief Executive Officer (together, “Interim CEO”), effective as of April 9, 2025.
Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025
appointed Jon P. Stonehouse, the Company’s Chief Executive Officer, to serve as Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of the Effective Date.
On April 10 2025, the Board of Directors of the Company appointed Mark Frost to serve as Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation (the “Effective Date”).
On April 7, 2025, Jennifer Cote notified the Company of her resignation as Chief Financial Officer and Treasurer.
On April 10, 2025, Allison Transmission Holdings, Inc. (the “Company” or “Allison”) announced the appointment of Scott A. Mell to serve as the Company’s Chief Financial Officer and Treasurer, effective April 14, 2025.
will be succeeded by James (Jim) Nickolas as of the Transition Date
Oddone Incisa, the Company’s Chief Financial Officer, will step down effective May 6, 2025
On April 4, 2025, at a meeting (the “ Meeting ”) of the board of directors (the “ Board ”) of Graphjet Technology (the “ Company ”), Aiden Lee Ping Wei resigned from his positions as Chief Executive Officer and member of the Board of the Company (the “ CEO Resignation ”).
the Board appointed Chris Lai Ther Wei, who had previously been appointed to the positions of Deputy Chief Executive Officer and Chief Financial Officer of the Company, as Chief Executive Officer
On April 10, 2025, the Board appointed Marcello Padula to serve as the Chief Financial Officer of the Company, effective on May 7, 2025.
On April 4, 2025, Robert Folino notified the board of directors (the “Board”) of Bleichroeder Acquisition Corp. I (the “Company”) of his resignation as Chief Financial Officer of the Company, effective on May 7, 2025.
Mr. Topper will continue to serve as the Company’s Chief Financial Officer until the effective date of Ms. Vairavan’s appointment and will provide transition support through his departure on May 15, 2025.
On April 10, 2025, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of Latha Vairavan, the Company’s current Vice President, Finance and Corporate Controller, as the Company’s Senior Vice President and Chief Financial Officer, effective immediately prior to the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission.
On April 7, 2025, Fariyal Khanbabi ceased to be employed as Chief Financial Officer of Microvast Holdings, Inc.
On April 3, 2025, the Company made an offer of employment to Carl T. “Pat” Schultz pursuant to which Mr. Schultz will serve as the Company’s Chief Financial Officer
On April 9, 2025 Neogen Corporation (the “Company”) announced that John Adent, the Company’s CEO and President, will be stepping down.
On April 8, 2025, Littelfuse, Inc. (the “Company”) and Meenal Sethna, Executive Vice President and Chief Financial Officer of the Company, agreed to Ms. Sethna’s separation from employment with the Company, effective September 1, 2025 (the “Separation Date”).
On April 7, 2025, the Board of Directors of Madison Square Garden Entertainment Corp. (the “Company”) appointed David Collins as Executive Vice President and Chief Financial Officer effective April 14, 2025
the board of directors of National Research Corporation, a Delaware corporation (the “Company”) appointed Trent Green as our Chief Executive Officer and to serve as a director, both effective June 1, 2025.
the appointment of Todd Yoder as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, effective April 14, 2025.
On March 21, 2025, Jessica Buss notified Argo Group International Holdings, Inc. (the “Company”) of her resignation as Chief Executive Officer of the Company, effective immediately.
On April 7, 2025, the Board of Directors of the Company also determined that Thomas F. Cowhey, currently the Executive Vice President and Chief Financial Officer of CVS Health, will cease to serve as Executive Vice President and Chief Financial Officer of CVS Health as of the Effective Date.
On April 7, 2025, the Board of Directors of CVS Health Corporation (the “Company” or “CVS Health”) appointed Brian O. Newman to serve as Executive Vice President and Chief Financial Officer of CVS Health, effective May 12, 2025 (the “Effective Date”).
On April 4, 2025, HireQuest, Inc. (the "Company") appointed, effective May 31, 2025, C. David Hartley to serve as Chief Financial Officer.
Steve Crane, the Company's Chief Financial Officer, informed the Company of his intention to retire from his role effective May 31, 2025.
On April 4, 2025, Kanwardev Raja Singh Bal notified indie Semiconductor, Inc. (the “Company”) of his resignation as Chief Financial Officer, Executive Vice President and Chief Accounting Officer of the Company.
On April 3, 2025, the Board of Directors (the “ Board ”) of the Company determined by unanimous written consent to appoint Ms. Dai as the Company’s permanent Chief Financial Officer (“ CFO ”), effective April 3, 2025.
On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.